InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | 2026-05-14 | Grossman Jerrold B | Director | Purchase | 12.5K | $8.01 | $100K | 513.9K | View ↗ | |
| 2026-05-11 | 2026-05-12 | Grossman Jerrold B | Director | Purchase | 12.5K | $8.01 | $100K | 501.4K | View ↗ | |
| 2026-03-16 | 2026-03-17 | Grossman Adam S | Director & President and CEO | Sale | 21.0K | $15.16 | $318K | 2.11M | View ↗ | |
| 2026-03-09 | 2026-03-10 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | Sale | 10.1K | $15.63 | $158K | 466.6K | View ↗ | |
| 2026-03-06 | 2026-03-09 | ELMS STEVE | Director | Purchase | 7,000 | $15.39 | $108K | 2.05M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| REVENUES | $510.2M+19.6% | $426.5M+65.2% | $258.2M+67.6% | $154.1M+90.4% | $80.9M |
| Cost of product revenue | $217.4M+5.1% | $206.9M+22.2% | $169.3M+42.5% | $118.8M+48.9% | $79.8M |
| Gross profit | $292.8M+33.3% | $219.6M+146.8% | $88.9M+152.2% | $35.3M+2906.4% | $1.2M |
| Research and development | $4.8M+162.7% | $1.8M-45.1% | $3.3M-8.7% | $3.6M-0.9% | $3.6M |
| Plasma center operating expenses | $4.8M+13.9% | $4.2M-0.5% | $4.3M-76.1% | $17.8M+45.2% | $12.3M |
| Amortization of intangible assets | $144K-62.9% | $388K-46.4% | $724K+1.3% | $715K+0.0% | $715K |
| Selling, general and administrative | $91.6M+23.5% | $74.1M+25.6% | $59.0M+12.5% | $52.5M+22.3% | $42.9M |
| Total operating expenses | $101.3M+25.8% | $80.6M+19.7% | $67.3M-9.8% | $74.6M+25.3% | $59.5M |
| INCOME FROM OPERATIONS | $191.4M+37.7% | $139.0M+542.5% | $21.6M+155.0% | -$39.4M+32.6% | -$58.4M |
| Interest income | $1.9M-10.8% | $2.1M+29.7% | $1.6M+3493.3% | $45K+28.6% | $35K |
| Interest expense | -$7.1M+49.0% | -$13.9M+44.3% | -$25.0M-29.8% | -$19.3M-47.7% | -$13.1M |
| Loss on extinguishment of debt | -$3.3M-168.4% | -$1.2M+95.3% | -$26.2M-292.4% | -$6.7M | $0 |
| Other expense | -$212K-9.8% | -$193K+32.8% | -$287K+54.8% | -$635K-152.0% | -$252K |
| Other expense, net | -$8.8M+33.8% | -$13.3M+73.4% | -$49.9M-87.9% | -$26.5M-99.9% | -$13.3M |
| INCOME (LOSS) BEFORE INCOME TAXES | $182.7M+45.3% | $125.7M+545.2% | -$28.2M+57.2% | -$65.9M | — |
| Income tax expense (benefit) | $35.7M+149.6% | -$72.0M | $0 | $0 | — |
| NET INCOME (LOSS) | $146.9M-25.7% | $197.7M+800.0% | -$28.2M+57.2% | -$65.9M+8.0% | -$71.6M |
| BASIC EARNINGS (LOSS) PER COMMON SHARE (in Dollars per share) | $620-27.1% | $850+753.8% | -$130+60.6% | -$330+35.3% | -$510 |
| DILUTED EARNINGS (LOSS) PER COMMON SHARE (in Dollars per share) | $600-25.9% | $810+723.1% | -$130+60.6% | -$330+35.3% | -$510 |
| Basic (in Shares) | $238.30B+2.2% | $233.08B+4.1% | $223.98B+13.2% | $197.87B+41.8% | $139.58B |
| Diluted (in Shares) | $244.90B+0.6% | $243.34B+8.6% | $223.98B+13.2% | $197.87B+41.8% | $139.58B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Here’s What Analysts Think About ADMA Biologics (ADMA)
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
New Strong Sell Stocks for May 14th
Canaccord Cuts PT on ADMA Biologics Inc. (ADMA) But Remains a Buy on Shares